Nuvalent, INC Form 4 insider transactions

Nuvalent, Inc.'s Chief Scientific Officer, Henry E. Pelish, executed pre-planned transactions in June 2025, exercising stock options and subsequently selling a portion of the acquired shares under a Rule 10b5-1 trading plan.

James E. Flynn and Deerfield Management Company, L.P. reported the acquisition of Nuvalent, Inc. Class A Common Stock and stock options through compensation grants to affiliated directors.

Nuvalent, Inc. Director Cameron Wheeler has filed a Form 4 detailing the future acquisition of restricted stock units and stock options effective June 18, 2025, under a pre-arranged Rule 10b5-1 plan.

Nuvalent, Inc. Director Sapna Srivastava was granted 2,647 restricted stock units and 4,147 stock options, aligning her interests with shareholders.

Nuvalent, Inc. Director Matthew Shair has filed a Form 4 detailing the future acquisition of restricted stock units and stock options, along with his updated beneficial ownership.

Nuvalent, Inc. Director Anna Protopapas was granted 2,647 restricted stock units and options to purchase 4,147 shares of Class A Common Stock, effective June 18, 2025, as part of her compensation.

Nuvalent, Inc. Director Joseph Pearlberg reported the acquisition of 2,647 restricted stock units and 4,147 stock options, which vest based on continued service, as part of his compensation.

Nuvalent, Inc. Director Michael L. Meyers was granted 2,647 restricted stock units and options to purchase 4,147 shares of Class A Common Stock, aligning his interests with shareholders.

Nuvalent, Inc. Director Grant C. Bogle has acquired 2,647 shares of Class A Common Stock via restricted stock units and 4,147 stock options, as reported in a recent SEC Form 4 filing.

Nuvalent, Inc. Director Christy J. Oliger was granted 3,971 restricted stock units and options to purchase 6,119 shares of Class A Common Stock, aligning her interests with shareholders.

Nuvalent, Inc.'s President and CEO, James Richard Porter, reported the exercise of stock options and subsequent sale of Class A Common Stock totaling over $2 million, all conducted under a pre-arranged Rule 10b5-1 trading plan.

Nuvalent, Inc.'s Chief Scientific Officer, Henry E. Pelish, executed a pre-arranged Rule 10b5-1 trading plan on June 6, 2025, exercising stock options and subsequently selling 200 shares of Class A Common Stock.

Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, engaged in pre-planned transactions on May 29, 2025, exercising stock options and simultaneously selling an equivalent number of Class A Common Stock shares under a Rule 10b5-1 trading plan.

James Richard Porter, President and CEO of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Nuvalent's CEO, James Richard Porter, executed multiple sales of Class A Common Stock on April 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on March 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.

James Richard Porter, CEO of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Director Matthew Shair of Nuvalent, Inc. executed sales of Class A Common Stock on February 24, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Nuvalent's CEO, James Richard Porter, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., exercised stock options on January 31, 2025, acquiring 3,120 shares of Class A Common Stock.

Director Matthew Shair of Nuvalent, Inc. executed multiple sales of Class A Common Stock on January 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Nuvalent's CEO, James Porter, executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., reports the acquisition and disposition of Class A Common Stock and stock options.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., sold shares of Class A Common Stock to cover tax obligations following the vesting of restricted stock units.

Deborah Ann Miller, Chief Legal Officer at Nuvalent, Inc., executed multiple stock transactions including the vesting of restricted stock units and sales to cover tax obligations.

Christopher Turner, Chief Medical Officer of Nuvalent, Inc., reports the acquisition and disposition of Class A Common Stock and stock options on January 6, 2025, including sales to cover tax obligations.

Alexandra Balcom, CFO of Nuvalent, Inc., reports the acquisition and disposition of Class A Common Stock and stock options on January 6, 2025.

Nuvalent's CEO, James Richard Porter, reports the acquisition and disposition of Class A Common Stock and stock options, including sales to cover tax obligations.